You are here

Stabilized, Freeze Dried Bacteriophage for use in Austere Environments

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: HT9425-23-C-0022
Agency Tracking Number: H2-0715
Amount: $1,099,973.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: DHA21C-003
Solicitation Number: 21.C
Timeline
Solicitation Year: 2021
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-03-08
Award End Date (Contract End Date): 2025-07-09
Small Business Information
20 New England Business Center
Andover, MA 01810-1111
United States
DUNS: 073800062
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Emily Gong
 (978) 738-8289
 egong@psicorp.com
Business Contact
 William Marinelli
Phone: (978) 738-8226
Email: marinelli@psicorp.com
Research Institution
 University of Connecticut
 Robin Bogner
 
2374 Alumni Drive
Storrs, CT 06269-0000
United States

 (860) 486-2163
 Domestic Nonprofit Research Organization
Abstract

Physical Sciences Inc. (PSI), in collaboration with the University of Connecticut (UConn) including Dr. Robin Bogner, with expertise in pharmaceutical freeze drying and sustained release for novel pharmaceutical formulations, and Dr. Carolyn Teschke, with expertise in bacteriophage biology, proposes to demonstrate long-term stability of bacteriophages between storage temperatures of -20°C and +45°C and to develop a bandage treatment system that will allow for sustained release of the bacteriophages for 1-3 days. During Phase I, we developed a formulation and process for lyophilization, or freeze drying, of bacteriophages for improved stability to enable bacteriophage treatments in austere environments. The Phase II program will build on this work by developing sterile bandages containing freeze-dried bacteriophages for application is austere environments for use by the DoD and ultimately by the general civilian population. The Phase II program will solve a number of technical challenges that were identified during the Phase I program. These include bacteriophage stability at the extremes of the temperature range of interest and reduced stability of the strain of Myoviridae bacteriophage tested in the Phase I program. The Phase II program will also expand on the Phase I work by additional development of a material system that can be implemented within a bandage to provide sustained release of bacteriophages.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government